Quality Management Implementation Status


Minhai Biologics consistently places product quality at the forefront. While complying with China’s vaccine regulatory framework, the company has thoroughly incorporated and drawn upon relevant standards from the WHO, ICH, PIC/S, and EU GMP, establishing a comprehensive quality management system that covers the entire product lifecycle—spanning research and development, technology transfer, commercial-scale production, and post‑marketing surveillance—thereby ensuring robust assurance of product safety, efficacy, and controllable quality.

Minhai Biologics consistently adopts a forward-looking perspective, keeps pace with the times, and closely monitors the latest developments in domestic and international regulations as well as industry trends. The company continuously refines its quality management system across the entire product lifecycle, ensuring robust support for ongoing innovation and sustained growth.